All In Biotech

Drug Trial Radar · NCT07427680

Study of TGM-312-SC01 in Healthy Participants and Adults With MASH

RESTORE-MASH: A Phase 1/2 Randomized, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of TGM-312-SC01 in Healthy Participants and Adults With MASH

Last checked: Nov 20, 2026Latest source record: May 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

99

Planned (sponsor's estimate)

Start

Mar 3, 2026

Primary completion

Mar 2028

Study completion Jun 2028

Sponsor

Lead sponsor
Tangram Therapeutics PlcIndustry
Sponsor type
Industry
First posted
Feb 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) effects of single ascending doses of TGM-312-SC01 in healthy adults and multiple ascending doses in patients with metabolic dysfunction-associated steatohepatitis (MASH).

Conditions

  • Healthy Participants
  • MASH - Metabolic Dysfunction-Associated Steatohepatitis

Interventions

  • TGM-312-SC01Drug

    TGM-312-SC01 is an investigational medicinal product administered by subcutaneous injection according to a protocol-defined regimen.

  • PlaceboDrug

    Placebo administered by subcutaneous injection according to a protocol-defined regimen.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of treatment-emergent adverse events [Safety and tolerability]Time frame: From start of study drug administration through 16 weeks after the last study drug administration.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Richmond Pharmacology

    London, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.